Naxitamab, sold under the brand name Danyelza, is an anti-cancer medication. It is a monoclonal antibody used in combination with granulocyte-macrophage...
8 KB (592 words) - 01:45, 18 May 2024
tesirine Mirvetuximab soravtansine Mogamulizumab Moxetumomab pasudotox Naxitamab Necitumumab Nivolumab Olaratumab Oportuzumab monatox Pembrolizumab Polatuzumab...
12 KB (760 words) - 05:52, 10 June 2024
which may complement existing retinoid therapies. In November 2020, naxitamab was approved for medical use in the United States in combination with...
68 KB (7,168 words) - 09:40, 11 April 2024
humanized DLL4 and VEGFA cancer Navivumab mab human Hemagglutinin (influenza) Naxitamab Danyelza humanized c-Met Y high-risk neuroblastoma and refractory osteomedullary...
135 KB (4,054 words) - 22:35, 2 July 2024
L01FX18 Amivantamab L01FX19 Sabatolimab L01FX20 Tremelimumab L01FX21 Naxitamab L01FX22 Loncastuximab tesirine L01FX23 Tisotumab vedotin L01FX24 Teclistamab...
12 KB (877 words) - 15:36, 25 January 2024
mutations Lumasiran Alnylam Pharmaceuticals primary hyperoxaluria type 1 Naxitamab-gqgk Y-mAbs Therapeutics relapsed or refractory high-risk neuroblastoma...
34 KB (180 words) - 22:09, 8 April 2024
tesirine Mirvetuximab soravtansine Mogamulizumab Moxetumomab pasudotox Naxitamab Necitumumab Nivolumab Olaratumab Oportuzumab monatox Pembrolizumab Polatuzumab...
12 KB (758 words) - 23:46, 14 March 2024
Lintuzumab§ Lorvotuzumab mertansine§ Lumretuzumab§ Matuzumab§ Milatuzumab§ Naxitamab Nimotuzumab† Obinutuzumab Ocaratuzumab§ Otlertuzumab§ Onartuzumab§ Oportuzumab...
5 KB (368 words) - 22:00, 19 October 2020
Lintuzumab§ Lorvotuzumab mertansine§ Lumretuzumab§ Matuzumab§ Milatuzumab§ Naxitamab Nimotuzumab† Obinutuzumab Ocaratuzumab§ Otlertuzumab§ Onartuzumab§ Oportuzumab...
4 KB (241 words) - 11:41, 22 April 2022
Lintuzumab§ Lorvotuzumab mertansine§ Lumretuzumab§ Matuzumab§ Milatuzumab§ Naxitamab Nimotuzumab† Obinutuzumab Ocaratuzumab§ Otlertuzumab§ Onartuzumab§ Oportuzumab...
3 KB (129 words) - 01:04, 19 July 2023